MISSISSAUGA, ON, June 3 /CNW/ - Nuvo Research Inc. (TSX: NRI), a Canadian
drug development company focused on the research and development of drug
products delivered to and through the skin using its topical and transdermal
drug delivery technologies, and Paladin Labs Inc. (TSX: PLB), a leading
Canadian specialty pharmaceutical company, today announced that Health Canada
has approved a new dosing regimen for Pennsaid(R) (topical diclofenac).
Paladin sells and markets Pennsaid in Canada, having acquired exclusive
Canadian Pennsaid rights from Nuvo in August 2005.
The new dosing regimen of Pennsaid(R) will be 50 drops per knee, 3 times
a day, as an alternative to the existing approved dosing regimen of 40 drops
per knee, 4 times a day. Pennsaid(R) is now the only topical NSAID approved in
Canada with this new improved dosing regimen. Pennsaid had Canadian sales of
$10.6 million last year and has been sold in Canada since May 2003.
"Pennsaid(R) is a proven effective treatment for Osteoarthritis of the
knee," said Dr. Philip Baer, a Rheumatologist practicing in Ontario. "The
newly approved dosing regimen of 50 drops TID (three-times-per-day) will make
it easier for patients to use Pennsaid(R) to manage their pain, as compared to
applying 40 drops QID (four-times-per-day). TID dosing can improve patient
compliance, which is one of the most important factors in ensuring effective
"The new improved dosing regimen of Pennsaid(R) is a significant clinical
advantage," said Henrich Guntermann, Nuvo's President and CEO. "We are eager
to replicate Pennsaid's Canadian success in the U.S. market and continue to
work diligently on obtaining U.S. FDA approval."
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a leading
specialty pharmaceutical company focused on developing, acquiring or
in-licensing innovative pharmaceutical products for the Canadian market. With
this strategy, a focused national sales team and proven marketing expertise,
Paladin has evolved into one of Canada's leading specialty pharmaceutical
companies. Paladin's shares trade on the Toronto Stock Exchange under the
symbol PLB. For more information about Paladin, please visit the Paladin web
site at www.paladinlabs.com.
About Nuvo Research Inc.
Nuvo is focused on the research and development of drug products
delivered to and through the skin using its topical and transdermal drug
delivery technologies. Nuvo's lead product is Pennsaid(R), a topical
non-steroidal anti-inflammatory (NSAID) used for the treatment of
osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to
create a portfolio of topical and transdermal products targeting a variety of
Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company
headquartered in Mississauga, Ontario, with manufacturing facilities in
Varennes, Québec and Wanzleben, Germany and a research and development Center
in San Diego California. For more information, please visit
This release may contain forward-looking statements, subject to risks and
uncertainties beyond management's control. Actual results could differ
materially from those expressed here. Risk factors are discussed in the
Companies' annual information forms filed with the securities commissions in
each of the provinces of Canada. The Companies referred to herein undertake no
obligation to revise forward-looking statements in light of future events.
For further information:
For further information: about Paladin, please contact: Samira Sakhia,
Chief Financial Officer, Paladin Labs Inc., Tel: (514) 340-5067, email:
email@example.com; For more information about Nuvo, please contact:
Investor Relations, Christina Bessant, Equicom Group Inc., Tel: (416) 815-0700
x269, email: firstname.lastname@example.org